Myelodysplastic Syndromes (MDS): Recent Updates and Evolving Treatment Paradigms : Episode 11

News

Video

July 28, 2023

ESA Outcomes by SF3B1 Mutation Status in Lower-Risk MDS

Author(s):

Dr Madanat reviews data from an abstract presented at ASCO 2023 on the outcomes of ESA therapy in patients with SF3B1-mutated lower-risk MDS.

EP: 1.Diagnosing Myelodysplastic Syndromes (MDS)

EP: 2.Risk Stratification of MDS

EP: 3.First-Line Treatment Options for Lower-Risk MDS With Symptomatic Anemia

EP: 4.Initiating Treatment for Lower-Risk MDS With Symptomatic Anemia

EP: 5.Monitoring Treatment With ESAs for Lower-Risk MDS With Symptomatic Anemia

EP: 6.Second-Line Treatment Options for Lower-Risk MDS With Symptomatic Anemia

EP: 7.Patient Profile: A 75-Year-Old Man With Lower-Risk MDS and Symptomatic Anemia

EP: 8.Treatment Approaches for Lower-Risk MDS With Symptomatic Anemia

EP: 9.Patient Profile: A 79-Year-Old Man With Lower-Risk MDS and a KRAS Mutation

EP: 10.Treatment Approaches for Lower-Risk MDS With RAS Mutations

Now Viewing

EP: 11.ESA Outcomes by SF3B1 Mutation Status in Lower-Risk MDS

EP: 12.Luspatercept for Lower-Risk MDS: Data From the COMMANDS Trial

EP: 13.Imetelstat for Lower-Risk MDS: Data From the IMerge Trial

EP: 14.Oral HMAs in Lower-Risk MDS Treatment

EP: 15.IRAK1 and IRAK4 Inhibitors for the Treatment of Lower-Risk MDS

EP: 16.Key Trials in the Treatment of Higher-Risk MDS

EP: 17.Final Thoughts on Recent Data Updates in MDS

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Related Content

March 24th 2025

Emerging Therapies in Myelofibrosis Could Extend Beyond JAK Inhibitors

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital

November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

Physical Functioning Measures With CAR T-Cell Therapy in NHL | Image Credit: © LASZLO– stock.adobe.com

March 23rd 2025

Physical Functioning Measures May Predict Survival Outcomes, ICANS Risk With CAR T-Cell Therapy in NHL

March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

R/R DLBCL | Image Credit: © LASZLO - stock.adobe.com

March 20th 2025

FDA Grants Fast Track Designation to Azer-Cel for R/R DLBCL

Image Credit: © Corona Borealis - stock.adobe.com

March 18th 2025

FDA Grants Orphan Drug Designation to Bexobrutideg in Waldenström Macroglobulinemia